Every Form 4 that TransDigm Group Incorporated (TDG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TDG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TDG filings page.
TransDigm Group Inc. director Kevin Stein, through the Fortuna Trust dated June 1, 2018, reported option exercises and share sales dated 01/05/2026. The trust exercised 17,940 stock options at an exercise price of $105.88 per share and another 7,060 options at $341.28 per share, both relating to TransDigm common stock.
On the same date, the trust sold multiple blocks of TransDigm common stock in open-market transactions at prices ranging from about $1,361.59 to $1,387.035 per share, reported as weighted average prices for each sale line. After these transactions, the trust indirectly held 8,158 shares of TransDigm common stock and 42,940 stock options, all reported as indirectly owned through the Fortuna Trust.
TransDigm Group Inc. reported an insider stock transaction by its Co-Chief Operating Officer, Patrick J. Murphy. On 01/02/2026, Murphy exercised a stock option to acquire 290 shares of TransDigm common stock at an exercise price of $269.42 per share. On the same day, he sold 290 shares of common stock at a price of $1,329.03 per share.
After these transactions, Murphy beneficially owned 1,055 shares of TransDigm common stock directly and held 1,450 stock options as derivative securities.
TransDigm Group Inc.’s Co-Chief Operating Officer reported an option exercise and related stock sales. On 12/15/2025, he exercised 3,900 stock options at an exercise price of $284.97 per share and received the same number of TransDigm common shares. The filing then shows multiple open-market sales of TransDigm common stock that day in small blocks at weighted-average prices within ranges from about $1,282.12 to $1,311.40. After these transactions, he directly beneficially owned 3,600 shares of common stock and held 39,200 stock options that remain outstanding.
TransDigm Group Inc. director reports option exercise and share sales. On 12/10/2025, the reporting person exercised a stock option for 4,700 shares of TransDigm common stock at an exercise price of $66.47 per share and acquired those shares. The same day, they sold a total of 4,700 shares in three open market transactions: 580 shares at a weighted average price of $1,289.3197, 4,046 shares at $1,290.2959, and 74 shares at $1,291.0322, leaving 5,625 shares held directly.
The option covered 4,700 shares of common stock, was exercisable beginning 09/30/2018, and was set to expire on 11/08/2027. After these transactions, the reporting person also continues to hold significant indirect ownership, including 366,141 shares through Stockbridge Fund, L.P., 68,139 shares through Stockbridge Partners LLC, and 60,246 shares through family trusts.
TransDigm Group director Robert J. Small reported sales of the company’s common stock in a Form 4 filing. On 12/09/2025, entities associated with him sold 75,673 and 15,280 shares of TransDigm common stock at $1,335.72 per share.
After these transactions, 366,141 shares are held indirectly through Stockbridge Fund, L.P., 68,139 shares through Stockbridge Partners LLC, and 60,246 shares through certain family trusts, with an additional 5,625 shares held directly. The filing states that Small may be deemed to share voting and dispositive power over these holdings but disclaims beneficial ownership beyond any pecuniary interest.
TransDigm Group Inc. reported an insider stock transaction involving a company director. A stock option for 17,526 shares of common stock with an exercise price of $105.88 was exercised on 12/04/2025 and held indirectly through the Fortuna Trust dated June 1, 2018.
The trust then reported a series of open-market sales of TransDigm common stock on the same date at weighted average prices ranging from about $1,360.0000 to $1,367.2300 per share. After these transactions, the trust held 8,158 shares of TransDigm common stock and 37,940 derivative securities beneficially owned. The filing notes that the reported sale prices are weighted averages and that full price breakdowns for each trade within the ranges are available upon request.
TransDigm Group Inc. insider transaction: A company officer serving as Co‑Chief Operating Officer reported an option exercise and related stock sale. On 12/01/2025, the insider exercised a stock option to acquire 290 shares of TransDigm common stock at an exercise price of $269.42 per share, then on the same date sold 290 shares of common stock at a price of $1,351.06 per share.
After these transactions, the insider directly beneficially owned 1,055 shares of TransDigm common stock and 1,740 stock options. The filing was made as a Form 4 by one reporting person, reflecting routine insider equity activity.
TransDigm Group Inc. filed a Form 4 reporting equity transactions by director Kevin Stein through the Fortuna Trust dated June 1, 2018. On 11/28/2025, the trust exercised a stock option for 4,592 shares of TransDigm common stock at an exercise price of $105.88 per share. The option relates to an award originally exercisable from 09/30/2018 and expiring on 04/25/2028, and its exercise price has been adjusted for dividends declared since August 1, 2022.
On the same date, the trust reported sales of TransDigm common stock in three transactions of 2,997, 1,545 and 50 shares at volume-weighted average prices of approximately $1,360.44, $1,361.25 and $1,362.43, respectively, within narrow intraday price ranges. Following these transactions, the Fortuna Trust indirectly held 8,158 shares of TransDigm common stock.
TransDigm Group Inc. (TDG) director Kevin Stein, through the Fortuna Trust dated June 1, 2018, reported stock option exercises and related share sales. On 11/25/2025, the trust exercised 4,187 stock options at an exercise price of $105.88 per share and then sold 4,097 common shares at a weighted average price of $1,360.5495 per share, plus an additional 90 shares at a weighted average price of $1,361.8702 per share. On 11/26/2025, the trust exercised another 30 stock options at $105.88 per share and sold 30 shares at $1,360.06 per share. After these transactions, the trust beneficially owned 8,158 TDG common shares and 60,058 stock options indirectly.
TransDigm Group Inc. (TDG) director Michael Graff reported a gift of 340 shares of common stock on 11/21/2025, as shown on this Form 4. The transaction, coded "G" for gift, was at a reported price of $0 per share.
After this transaction, Graff directly owns 1,653 TransDigm common shares. He also reports indirect ownership of 5,096 shares held by The 2012 Carol Ostrow GST Trust created by his spouse for their children, and 7,000 shares held by certain other trusts created for the benefit of their children, for which he serves as trustee.
TransDigm Group (TDG) director Form 4 shows an option exercise and matching share sale by an affiliated trust. On 11/21/2025, the Fortuna Trust dated June 1, 2018 exercised 230 stock options for TransDigm common stock at an exercise price of $105.88 per share and acquired 230 shares. The trust then sold 230 common shares at an average price of $1,360.3096 per share, leaving it with 8,158 shares of indirect beneficial ownership. Following the transaction, the trust continues to hold 64,275 stock options indirectly, with an exercise price of $105.88 and an expiration date of 04/25/2028.
TransDigm Group (TDG) director Kevin Stein, reporting through the Fortuna Trust dated June 1, 2018, disclosed an option exercise and related share sales. On 11/20/2025, the trust exercised a stock option for 1,104 shares of common stock at an exercise price of $105.88 per share, originally granted in 2018 and expiring in 2028. The same day, the trust sold 655 shares at an average $1,360.3298, 400 shares at an average $1,361.5239, and 49 shares at an average $1,363.2231, with each sale reported as an average weighted price over a narrow range. After these transactions, the trust beneficially owned 8,158 shares of TransDigm common stock and 64,505 stock options, all reported as indirect ownership through the trust.
TransDigm Group Inc. (TDG) director Kevin Stein reported an option exercise and related share sales on 11/18/2025, all held indirectly through the Fortuna Trust dated June 1, 2018. A stock option for 7,191 shares of common stock was exercised at an adjusted price of $105.88 per share.
The shares acquired on exercise were then sold in multiple open-market transactions the same day, using weighted-average prices, with example sales including 3,580 shares at $1,360.2775 and 1,531 shares at $1,362.6356. The filing notes that the exercise price has been adjusted for dividends declared since August 1, 2022. After these transactions, the trust beneficially owns 8,158 shares of TransDigm common stock and 65,609 stock options.
TransDigm Group Inc. (TDG) Co-Chief Operating Officer Joel Reiss reported an insider transaction involving company common stock. On 11/17/2025, he exercised a stock option to acquire 3,900 shares of TransDigm common stock at an exercise price of $284.97 per share and, on the same date, reported a series of open-market sales of common stock at average prices generally between about $1,326.16 and $1,353.92 per share. Following these transactions, he reported beneficial ownership of 3,600 shares of common stock held directly and 43,100 stock options held directly.
TransDigm Group Inc. (TDG) director and President & CEO Michael J. Lisman reported multiple open‑market purchases of common stock on 11/14/2025 through the Michael Lisman Declaration of Trust dated January 31, 2023. The trust acquired 1,954 shares of TransDigm common stock in several transactions, including 600 shares at $1,334.13 and additional blocks at weighted average prices of $1,337.3825, $1,338.5578, $1,341.4904, $1,342.9335, and $1,344.7603 per share. After these transactions, Lisman is reported as beneficially owning 1,954 shares indirectly via the trust and 2,309 shares directly, with the direct holdings noted as previously omitted from an earlier report.
TransDigm Group (TDG) director W. Nicholas Howley, through the W. Nicholas Howley Family Trust, reported an option exercise and related stock sales. On 11/17/2025, the trust exercised a stock option for 2,736 shares of common stock at $50.92 per share, converting a derivative award into common shares. On the same date, the trust sold multiple small blocks of TransDigm common stock in open market transactions at weighted average prices generally between about $1,327 and $1,348 per share, as detailed in the footnotes. After these transactions, the trust held 21,547.513 shares of TransDigm common stock indirectly on behalf of the reporting person.
TransDigm Group (TDG) reported that director David Barr acquired 518 stock options on 11/04/2025 (transaction code A) with an exercise price of $1,291.97 per share. The options expire 11/04/2035 and vest 20% per year over five years beginning September 30, 2026, subject to achieving annual operating performance targets. Following the transaction, 518 derivative securities were beneficially owned, held directly.
TransDigm Group (TDG) filed a Form 4 for director Jane Cronin reporting a grant of stock options on 11/04/2025. The award covers 518 options with an exercise price of $1,291.97 per share.
The options vest 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets, and expire on 11/04/2035. Following this transaction, 518 derivative securities were beneficially owned, held directly.
TransDigm Group (TDG) reported a Form 4 for a director, reflecting a grant of stock options for 518 shares on November 4, 2025 with an exercise price of $1,291.97 per share and an expiration date of November 4, 2035.
The options vest at 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets. Following the grant, the reporting person held 518 derivative securities directly. The derivative security is a stock option on TransDigm common stock.
TransDigm Group (TDG) director Sean Hennessy reported a grant of 518 stock options on 11/04/2025 at an exercise price of $1,291.97 per share. The options vest 20% per year over five years beginning September 30, 2026, subject to annual operating performance targets, and expire on 11/04/2035. Following the grant, Hennessy beneficially owns 518 derivative securities, held directly.
TransDigm Group (TDG) reported an insider equity grant. Director W. Nicholas Howley received 518 stock options on 11/04/2025 at an exercise price of $1,291.97 per share. The options vest 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets, and expire on 11/04/2035. Following the grant, 518 derivative securities were beneficially owned directly.
TransDigm Group (TDG) — Form 4: Director Gary McCullough reported a grant of stock options on 11/04/2025. The award covers 518 options to purchase common stock at an exercise price of $1,291.97 per share, expiring on 11/04/2035. The filing lists 518 derivative securities beneficially owned following the transaction, held direct.
Per the footnote, the options vest 20% per year over five years beginning September 30, 2026, and are subject to annual operating performance targets.
TransDigm Group (TDG): Director Peter Palmer reported an equity grant on Form 4. He acquired stock options covering 518 shares on Nov 4, 2025 with an exercise price of $1,291.97 per share and an expiration date of Nov 4, 2035.
The options vest at 20% per year over five years, beginning Sept 30, 2026, and are subject to the achievement of annual operating performance targets each year. Following the transaction, 518 derivative securities were beneficially owned on a direct basis.
TransDigm Group (TDG) filed a Form 4 showing a director stock option grant. On 11/04/2025, a reporting person serving as a Director received stock options covering 518 shares at an exercise price of $1,291.97 per share. The options were reported as acquired (Code A) and are held directly.
The options expire on 11/04/2035 and vest at 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets in each year.
TransDigm Group (TDG) reported that director Robert Small acquired 518 stock options on November 4, 2025 (Transaction Code A) with an exercise price of $1,291.97 per share and an expiration date of November 4, 2035.
The options vest at 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets. Following the transaction, 518 derivative securities were beneficially owned, held directly.
TransDigm Group (TDG) reported an insider equity award. Director Kevin Stein acquired 518 stock options on 11/04/2025 with an exercise price of $1,291.97.
The options vest 20% per year over five years beginning September 30, 2026, subject to annual operating performance targets, and expire on 11/04/2035. Following the grant, 518 derivative securities were beneficially owned on a direct basis.
TransDigm Group (TDG) reported a Form 4 showing a grant of 26,450 stock options to a Co‑Chief Operating Officer at an exercise price of $1,291.97 on November 4, 2025.
The options vest 20% per year over five years beginning September 30, 2026, subject to annual operating performance targets, and expire on November 4, 2035. Following the transaction, 26,450 derivative securities were beneficially owned, held directly. Transaction code: A (award).
TransDigm Group (TDG) reported an insider equity award. Officer Armani Vadiee (GC, CCO, Secretary) received a grant of 17,100 stock options on 11/04/2025 at an exercise price of $1,291.97 per share. The options expire on 11/04/2035.
Per the grant terms, the options vest at 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets each year. Following the reported transaction, 17,100 derivative securities were beneficially owned, held direct.
TransDigm Group (TDG) reported a Form 4 for CFO Sarah Wynne showing a grant of 8,700 stock options on 11/04/2025 with an exercise price of $1,291.97 per share.
The options vest 50% in 2029 and 50% in 2030, subject to the achievement of annual operating performance targets, and expire on 11/04/2035. The filing lists direct ownership.
TransDigm Group (TDG) reported a Form 4 for Co‑Chief Operating Officer Joel Reiss, reflecting a grant of stock options for 9,700 shares at an exercise price of $1,291.97 on 11/04/2025.
The options expire on 11/04/2035 and are scheduled to vest 50% in 2029 and 50% in 2030, subject to achieving annual operating performance targets in each year. Following the grant, 9,700 derivative securities are beneficially owned on a direct basis.
TransDigm Group (TDG) disclosed a Form 4 showing its President & CEO, Michael Lisman, received stock option grants on 11/04/2025. Two awards were reported with an exercise price of $1,291.97 and an expiration of 11/04/2035 (Transaction Code: A). The first grant covers 75,696 options; the second covers 3,907 options. Both were acquired at $0 for the derivative security and are listed as Direct (D) ownership.
Vesting is performance-based: the 75,696 options vest 20% per year over five years beginning September 30, 2026, subject to annual operating performance targets. The 3,907 options vest 80% in 2026 and 20% in 2027, subject to similar targets.
TransDigm Group (TDG) reported an insider transaction by its Co‑Chief Operating Officer. On 11/03/2025, the officer exercised 290 stock options at $269.42 and on the same day sold 290 common shares at a weighted average price of $1,310 (within a range of $1,310.0000–$1,310.9999).
Following these transactions, the officer directly owns 1,055 common shares and holds 2,030 stock options outstanding.